Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alkermes plc
Argenx has aggressive market expansion plans for Vyvgart. It also has several late-stage challengers in what is becoming a dynamic market.
China's Zai Lab and Everest are still pursuing profitability on the commercialization of in-licensed assets, while BioNova and others have already bowed out of the game.
The European biotech is just getting started with its expansion plans for the drug in generalized myasthenia gravis, while multiple readouts in new autoimmune diseases are expected in 2024.
Perrigo doesn’t attempt to diminish significance of challenge to regain sales growth in formula market as it resets its plants. Analysts see formula business as only current impediment to stronger results.
- Other Names / Subsidiaries
- Rodin Therapeutics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.